title: [New treatments in vascular diseases other than age related macular degeneration].
abstract: Recent multicenter randomized studies about persistent macular edema in venous occlusions provided us with interesting results. Until now, the standard of care treatment of macular edema due to branch vein occlusion remained grid laser in contrast with central vein occlusion where the absence of treatment was still recommended. Score, Geneva, Bravo and Cruise studies recently provided us with the following results. Score study found triamcinolone to be interesting to treat macular edema due to central vein occlusion but not from branch occlusion. Geneva study assessed the effect of a delivery system of dexamethasone to treat macular edema due to venous occlusion whatever the clinical form with an improvement of visual acuity. Cruise and Bravo studies assessed the effect of ranubizumab, which was found to improve the visual acuity of macular edema due to either central or branch vein occlusions. At this stage we need comparative studies to precise the indication of these different approaches that remain perhaps complementary of laser treatment.
authors.affiliation: Service d'ophtalmologie, CHU de Dijon, 3, rue du Faubourg-Raines, 21000 Dijon, France. catherine.creuzot-garcher@chu-dijon.fr
authors.forename: C
authors.initials: C
authors.lastname: Creuzot-Garcher
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D003907:Dexamethasone / Q000008:administration & dosage; D006801:Humans; D008268:Macular Degeneration; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D012170:Retinal Vein Occlusion / Q000150:complications
chemical_list: D000305:Adrenal Cortex Hormones; D020533:Angiogenesis Inhibitors; D003907:Dexamethasone